BioMarin Pharmaceutical

BioMarin Pharmaceutical

World Rank (Aug-2026)
1775
Market Cap (Aug-2026)
13.039 Billion USD
World Rank (Jan-05-2024)
985
Market Cap (Jan-05-2024)
18.409 Billion USD
World Rank (Jul-30-2023)
1,112
Market Cap (Jul-30-2023)
16.444 Billion USD
World Rank (Jan-07-2022)
1,308
Market Cap (Jan-07-2022)
15.468 Billion USD
World Rank (Jan-01-2021)
1,130
Market Cap (Jan-01-2021)
15.918 Billion USD
Company Rank in Country in 2023
Rank in USA in July-2023 is 443
Headquarters Country
USA
Top Technology Companies in USA
Top Healthcare Companies in USA
Top Pharmaceutical Companies in USA
Nasdaq / NYSE Code
BMRN
CEO
Jean-Jacques Bienaime
Employee Count
3,082
Employee Count as of Date
As on 2022
Headquarters City/State
California
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
3,221 Million USD
Annual Operating Income in USD
409 Million USD
Annual Net Income in USD
349 Million USD
Annual Results for Period Ending
For year ending December-2025
Total Assets in USD
7,594 Million USD
Total Liabilities in USD
1,507 Million USD
Total Equity in USD
6,087 Million USD
Balance Sheet for Period Ending
As of December-2025
Business Sector
Healthcare
Pharmaceutical
HealthCare Products
Biotechnology
Technology
Company Website
BIOMARIN PHARMACEUTICAL INC
Wikipedia
Wikipedia
Yahoo
Yahoo @ Nasdaq
Company Profile

Biomarin Pharmaceutical is Pharmaceutical and Biotechnology Company with headquarters is in California, USA.

It develops innovate therapies and life-threatening rare diseases and medical conditions.It consists of seven commercial products for the treatment of various diseases.

As on 2022, Biomarin Pharmaceutical has 3,082 employees.

Biomarin Pharmaceutical annual revenue generated for period ending Dec-2022 was 2,096 million USD.

Biomarin Pharmaceutical GGross profit generating for the period of ending 2022 was 141 million USD.

Annual Results Summary

BIOMARIN PHARMACEUTICAL - Annual Result Summary - in Million USD

Year EndingTotal RevenueGross ProfitOperating IncomeNet Income
Dec-20222,0961,61241141
Dec-20211,8461,375-74 (Loss)-64 (Loss)
Dec-20201,8601,336(37) (Loss)859
Dec-20191,7041,345(100) (Loss)(24) (Loss)
Dec-20181,4911,176(124) (Loss)(77) (Loss)
Dec-20171,3141,072(15) (Loss)(117) (Loss)
Balance Sheet Summary

Total Assets as on Dec-2022 was 6,375 Million USD.

Total Liabilities as on Dec-2022 was 1,771 Million USD.

Total Equity as on Dec-2022 was 4,603 Million USD.

Founded Year
1997
Institutional Investors

Top 30 Institutional Holder Names in BIOMARIN PHARMACEUTICAL as on Jun-30-2022

RANKINSTITUTIONAL HOLDER NAMEDATESHARES HELDCHANGE (SHARES)CHANGE (%)VALUE (IN 1,000S)
1PRIMECAP MANAGEMENT CO/CA/06/30/20221,76,78,485-1,00,985-0.57%$1,676,628
2VANGUARD GROUP INC06/30/20221,68,44,8363,42,5932.08%$1,597,564
3DODGE & COX06/30/20221,50,07,063-27,936-0.19%$1,423,270
4BLACKROCK INC.06/30/20221,44,17,1014,59,0413.29%$1,367,318
5BAKER BROS. ADVISORS LP06/30/202276,20,49400%$722,728
6AMERIPRISE FINANCIAL INC06/30/202258,15,5774,75,1278.90%$551,549
7STATE STREET CORP06/30/202253,96,36615,9730.30%$511,791
8VIKING GLOBAL INVESTORS LP06/30/202250,52,59313,00,20034.65%$479,188
9CAPITAL RESEARCH GLOBAL INVESTORS06/30/202249,35,346-44,52,610-47.43%$468,068
10JANUS HENDERSON GROUP PLC06/30/202242,01,233-1,58,551-3.64%$398,445
11AVORO CAPITAL ADVISORS LLC06/30/202232,84,0002,49,0008.20%$311,455
12PARNASSUS INVESTMENTS, LLC06/30/202227,81,42055,4902.04%$263,790
13UBS GROUP AG06/30/202226,93,524-1,67,979-5.87%$255,454
14GEODE CAPITAL MANAGEMENT, LLC06/30/202224,71,81617,5790.72%$234,427
15NORGES BANK12/31/202123,49,5401,81,4958.37%$222,830
16BARCLAYS PLC06/30/202221,65,64020,01,3951218.54%$205,389
17PALO ALTO INVESTORS LP06/30/202220,61,373-78,241-3.66%$195,501
18ORBIMED ADVISORS LLC06/30/202216,99,71052,6803.20%$161,200
19JPMORGAN CHASE & CO06/30/202216,15,31724,5081.54%$153,197
20UBS ASSET MANAGEMENT AMERICAS INC06/30/202215,62,36510,7480.69%$148,175
21MILLENNIUM MANAGEMENT LLC06/30/202215,26,0032,24,01117.21%$144,726
22CAMBER CAPITAL MANAGEMENT LP06/30/202215,00,0002,00,00015.39%$142,260
23ADAGE CAPITAL PARTNERS GP, L.L.C.06/30/202213,75,000-1,00,000-6.78%$130,405
24BANK OF NEW YORK MELLON CORP06/30/202213,50,5146,07,46781.75%$128,083
25CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM06/30/202213,31,921-31,985-2.35%$126,319
26NORTHERN TRUST CORP06/30/202213,04,527-21,927-1.65%$123,721
27FORT WASHINGTON INVESTMENT ADVISORS INC /OH/06/30/202212,36,0591,0500.09%$117,228
28DEUTSCHE BANK AG\06/30/202212,26,5783,35,39737.64%$116,329
29CHARLES SCHWAB INVESTMENT MANAGEMENT INC06/30/202212,02,11074,0806.57%$114,008
301832 ASSET MANAGEMENT L.P.06/30/202212,01,8827,01,500140.19%$113,986
IPO Year
1999
Stock Exchange
Nasdaq
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Pharmaceutical Preparations

Share